CCR2 and renal fibrosis: The known roles of angiotensin 2 receptor type 1 and CCR2 individually in the progression of renal fibrosis, and the synergistic effect of simultaneous receptor inhibition combine to provide a strong therapeutic rationale for the combination approach used in this Phase II trial.